Analysts have given Fulcrum Therapeutics, Inc. (NASDAQ:FULC) an average rating of “Hold.”
According to Bloomberg Ratings, the nine research analysts who follow Fulcrum Therapeutics, INC (NASDAQ: FALC) have given the stock a ...
Tag: FULC, Analyst Rating
Fulcrum Therapeutics, Inc. is expected to earn $0.58 per share in fiscal year 2027. (NASDAQ:FULC)
Reports on the stock were issued not too long ago by research analysts originating from various institutions located worldwide.In a ...
MetLife Investment Management LLC purchases new Fulcrum Therapeutics, Inc. shares.
MetLife Investment Management LLC made a new investment in Fulcrum Therapeutics, INC (NASDAQ: FULC), as indicated by the company's most ...
Allspring Global Investments Holdings LLC has purchased 9,176 shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC).
According to the most recent statement that Allspring Global Investments Holdings LLC filed with the Securities and Exchange Commission, the ...
Analysts give Fulcrum Therapeutics, Inc. (NASDAQ:FULC) a “Moderate Buy” rating.
The eight investment banks and brokerages that are actively covering Fulcrum Therapeutics, Inc. (NASDAQ: FULC), according to data provided by ...
Analysts give Fulcrum Therapeutics, Inc. (NASDAQ:FULC) a “Moderate Buy” rating.
The eight investment banks and brokerages that are actively covering Fulcrum Therapeutics, Inc. (NASDAQ: FULC), according to data provided by ...
Fulcrum Therapeutics (NASDAQ:FULC) Shares Rise Due to Insider Buying
Because company insiders made purchases before the opening of trading on Monday, Fulcrum Therapeutics, Inc. (NASDAQ: FULC) rose substantially before ...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Major Shareholder Purchases Stock Worth $1,315,517.84
Ra Capital Management, L.P., a major shareholder in Fulcrum Therapeutics, Inc., recently purchased 180,703 shares of Fulcrum Therapeutics stock on ...